Ono Pharmaceutical has been granted a patent for a method of treating tumors, including gastric and lung cancers, through the combined administration of a liposomal composition containing Eribulin and a PD-1 antagonist, demonstrating unexpected antitumor effects. GlobalData’s report on Ono Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ono Pharmaceutical, Peptide pharmacophores was a key innovation area identified from patents. Ono Pharmaceutical's grant share as of June 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Combined treatment of tumors using eribulin and pd-1 antagonist
The granted patent US12036204B2 outlines a novel method for treating various types of tumors, specifically targeting gastric cancer, esophageal cancer, lung cancer, thymic carcinoma, and biliary tract cancer. The treatment involves administering a liposomal composition containing Eribulin or its pharmaceutically acceptable salt, alongside a PD-1 antagonist, which may be an anti-PD-1 or anti-PD-L1 antibody. The claims specify that the method can be applied to small cell lung cancer and intrahepatic cholangiocarcinoma, among other tumor types. The administration of these compounds can occur simultaneously, separately, continuously, or at specified intervals, providing flexibility in treatment protocols.
Further details in the claims specify the use of Eribulin mesylate as the active ingredient and identify specific anti-PD-1 antibodies, including Nivolumab, Pembrolizumab, Cemiplimab, Sintilimab, and Toripalimab. The patent also outlines dosage regimens for Nivolumab, with various administration schedules based on patient weight and treatment cycles. Notably, the method excludes non-small cell lung cancer from the treatment scope. Overall, this patent presents a comprehensive approach to combining chemotherapy and immunotherapy for enhanced efficacy in treating specific malignancies.
To know more about GlobalData’s detailed insights on Ono Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
